Sepsis

Sepsis
The challenges of science,
politics and society
Leopoldina Symposium
under the auspices of the Federal Minister Hermann Gröhe
10 – 11 March 2016
Foto: © Name des Fotografen
Main Lecture Hall (Aula)
Friedrich Schiller University Jena
Fürstengraben 1 | 07743 Jena
1
German National Academy of Sciences Leopoldina
Founded in 1652, the Leopoldina brings together some 1,500
outstanding scientists from about 30 countries. It is dedicated to
the advancement of science for the benefit of humankind and to
shaping a better future. In its role as the German National Academy of Sciences, the Leopoldina represents the German scientific community in international committees. It offers unbiased
scientific opinions on political and societal questions, publishing
independent studies of national and international significance.
The Leopoldina promotes scientific and public debate, supports
young scientists, confers awards for scientific achievements,
conducts research projects, and campaigns for the human rights
of persecuted scientists.
2
Introduction
Sepsis continues to cause millions of deaths worldwide of which
at least two million fatalities could be avoided each year by preventive measures such as vaccination of at risk populations, better
sanitation and clean care, as well as by early recognition and most
basic elements of care. In addition, at least 2 million sepsis survivors per year suffer from significant long term complications of
the syndrome. Currently, adequate treatment facilities for most of
these patients are missing. Despite its high and increasing incidence sepsis is poorly recognized by health authorities, health care
workers, policymakers, lay people and media. The implementation
of effective measures for sepsis control and the development of
improved infection and sepsis diagnostics, effective antimicrobials
and sepsis specific therapies are urgently needed.
3
We are pleased that this Leopoldina Symposium brings together
highly ranked policy makers, representatives of national and international health care authorities, most renowned clinical scientists,
basic researchers, representatives of highly innovative diagnostic
and pharmaceutic companies, media and communication experts
and sepsis survivors to learn from each other about the most effective ways to:
·Increase vaccination rates and adherence to hygienic standards
·Improve preparedness in case of further pandemics
·Increase awareness for sepsis among lay people and health
care providers
·Foster quality improvement projects in the hospital and
outpatient setting
·Implement antibiotic stewardship programs and stop the
misuse of antimicrobials
·Overcome the gap between resistance, novel and effective
antimicrobials
·Encourage the development of cost-effective diagnostics and
sepsis-specific therapeutics
·Develop and provide adequate treatment concepts for sepsis
sequelae
We are convinced that the outcomes of this symposium will increase the understanding of the need for national and international efforts, action plans and resolutions to fight life-threatening
infections and sepsis. For this reason, we cordially invite you to
join us for this meeting in the main auditorium of Friedrich Schiller
University Jena.
Michael Bauer
4
Axel Brakhage
Konrad Reinhart
Bundesregierung/Steffen Kugler
Foreword
Sepsis is a potentially life-threatening complication of an infection. It is one of the most
underestimated health risks. Every year,
more than 279,000 patients develop sepsis
in Germany and over 67,000 die of this condition. As a result, sepsis is the third most frequent cause of death in Germany. The Global
Sepsis Alliance puts the number of affected
per year at 30 million persons, more than one-fifth of whom die as
a result. However, even those patients who survive often suffer for
the rest of their lives from the physical and mental sequelae. This
development gives us reason for concern.
In recent years, the number of sepsis cases has been on the increase. There are several reasons for this. Owing to the prevailing
demographic trends, we now have more elderly patients who either have chronic diseases or need to undergo invasive treatment
and operations. Treatment procedures that lead to a weakening
of the immune system, such as chemotherapies, are becoming
increasingly frequent. Another reason for the rise in sepsis cases
is the increase in antibiotic resistance and the resulting failure of
hitherto successful treatments.
Appropriate measures could contribute to reducing the number of
sepsis cases. These measures include the vaccination of risk groups
5
against infectious diseases, stricter adherence to hygiene measures, early detection and treatment of sepsis, as well as a reduction
in antibiotic resistance by promoting the proper use of antibiotics.
Furthermore, it is necessary to educate both medical personnel
and citizens about this condition. Indeed, a major risk lies in the
lack of knowledge that prevails with respect to this disease. This is
why I am very pleased that the Leopoldina has chosen to organise
this ‚Sepsis Symposium‘. It is providing experts from all over the
world with an opportunity for exchange, both on the challenges
posed to science and policy and on the various strategies deployed
in fighting sepsis.
In a move to control antibiotic resistance and reduce healthcare-associated infections, the Federal Government has moved, in recent
years, to tighten laws, expand the existing tools and develop new
measures and opportunities. In collaboration with the Federal Ministry of Food and Agriculture and the Federal Ministry of Education and Research, the German Antibiotic Resistance Strategy ‚DART
2020‘ was drawn up and adopted by the Federal Cabinet in May
2015. Multi-disciplinary co-operation in combating antibiotic resistance in human and veterinary medicine is at the forefront of
the DART 2020 activities. A further key goal is better education of
the population with respect to antibiotic resistance and the provision of comprehensive information on the quality of hygiene in
hospitals. Furthermore, we intend to further develop the monitoring systems for antibiotic resistance and antibiotic use. This will
enable us to detect new pathogens and forms of resistance at an
early stage and thereby gain important data for the development
and adaptation of treatment and hygiene recommendations.
Together with other German-speaking health ministers, I am advocating that the World Health Assembly adopt a resolution on the
topic of sepsis in the coming year. Thanks to all of these measures,
we will be helping to decrease the incidence of the disease and
reduce sepsis-related mortality rates. This ‚Sepsis Symposium‘ will
certainly make a contribution towards achieving that goal.
Hermann Gröhe
Federal Minister
Member of the German
Bundestag
6
Program
Thursday, 10 March 2016
Opening session
Chairs:
E. Rietschel, Berlin / P. Suter, Geneva
Start: 10:30
Welcome and introduction
W. Tiefensee, TMWWDG
G. Berg, Leopoldina
W. Rosenthal, FSU
K. Benndorf, UKJ
10:50
Keynote Lecture:
Role of poverty and environment for public health
A. Steiner, Executive Director of United Nations Environment
Programme (UNEP) and Under-Secretary-General of the
United Nations
11:20
The German strategy for infection and sepsis control
L. H. Wieler, RKI
11:40
The WHO approach to sepsis control
N. Shindo, WHO
12:00
Lessons to be learned from the Ebola epidemic
T. Stöbe, MSF
12:20
The burden of sepsis in children
N. Kissoon, Canada
12:40
The burden of sepsis - a call to action
K. Reinhart, Jena
13:00 Lunch Break
7
The challenges of science
Chairs:
M. Quintel, Göttingen / T. Hein, Dallas
14:00
Challenges in the development of novel diagnostics and
therapeutics in sepsis
N. Riedemann, Jena
14:20
Challenges to preserve and develop effective antimicrobials
M. Pletz, Jena
14:40
Role and challenges of clinical sepsis research
S. Finfer, Australia
15:00
Lessons learned from cancer
M. Löffler, Leipzig
15:20
Lessons learned from cardiology
C. Schulze, Jena
15:40
Coffee Break
Novel approaches to sepsis control and health
promotion
Chairs:
C. Spies, Berlin / R. Rossaint, Aachen
16:00
The Surviving Sepsis Campaign approach to guideline
implementation
H. Gerlach, Berlin
16:20
The National Irish initiative to sepsis control
V. Hamilton, Ireland
16:40
The Scottish National Health Service approach to quality
improvement
K. Rooney, Scotland
8
Novel approaches to sepsis control and health
promotion II
Chairs:
K. Werdan, Halle / M. Weigand, Heidelberg
17:00
The NRC for Surveillance and Nosocomial infection’s approach
P. Gastmeier, Berlin
17:20
The Initiative for Quality in Medicine’s approach
A. Meier-Hellmann, Erfurt
17:40
The Center for Sepsis Control and Care’s approach
H. Rüddel, Jena
18:00
The perspective of a sepsis victim
A. Trumann, Heeslingen
Öffentlicher Abendvortrag
Moderation:
M. Bucher, Halle
19:00
Sepsis vermeiden und früh erkennen
F. M. Brunkhorst, Jena
9
Program
Friday, 11 March 2016
Novel approaches to sepsis control and health
promotion
Chairs:
B. Böttiger, Cologne / B. Löffler, Jena
08:30
The US approach to quality improvement for sepsis management
M. Levy, USA
08:50
The UK Sepsis Trust approach to awareness & quality improvement
R. Daniels, UK
09:10
Prepardness and the role of ICUs in the fight against pandemics
J. Marshall, Canada
09:30
The Turkish approach to improve sepsis awareness and sepsis
management.
N. Unal, Turkey
09:50
The role of media during health crises
J. Müller-Jung, FAZ
10:10
New approaches to vaccination and health promotion
C. Betsch, Erfurt
10:30
Coffee break
Roadmap for development of innovative vaccines,
diagnostics and therapeutics I
Chairs:
T. Koch, Dresden / L. Gattinoni, Milan
10
11:00
The German Center for Infection Research
D. Heinz, DZIF
11:20
The German Research Platform for Zoonoses
T. Mettenleiter, Greifswald
11:40
The SepNet Critical Care Trials group
J. Briegel, Munich
12:00
The CapNetz Trials group
T. Welte, Hannover
12:20
Lunch break
Roadmap for development of innovative vaccines,
diagnostics and therapeutics II
Chairs:
J. Schüttler, Erlangen / B. Löffler, Jena
13:00
The Progress Consortium
N. Suttorp, Berlin
13:20
The Center for Sepsis Control and Care
M. Bauer, Jena
13:40
The InfectControl Consortium
A. Brakhage, Jena
14:00
The InfectoGnostics Research Campus
J. Popp, Jena
14:20
The Center for Innovation Competence Septomics
O. Kurzai, Jena
14:40
The Center for Infectious Diseases and Infection Control
M. Pletz, Jena
15:00
Coffee break
11
Role of private public partnership for development
of innovative vaccines, diagnostics and therapeutics
Lessons learned and expectations of:
Chairs:
M. Hecker, Greifswald / H. van Aken, Münster
15:30
A researcher and later entrepreneur
E. Ermantraut, Blink GmbH Jena
15:50
An international diagnostics corporate
V. Liebenberg, Thermo Fisher Scientific Hennigsdorf/Berlin
16:10
A global medical products manufacturer
M. Lugan, B. Braun Melsungen AG
16:30
A biotech company
J. Struck, AdrenoMed AG Hennigsdorf/Berlin
16:50
A university spin-off
N. Riedemann, inflaRx Jena
17:10
Closing remarks
M. Bauer, Jena
12
Invited speakers and chairs
(in alphabetical order)
Bauer Michael, Prof. Dr.
Speaker and Chief-Executive Director, Center for Sepsis Control
and Care, Jena University Hospital
Jena, Germany
Benndorf Klaus, Prof. Dr.
Scientific Director, Dean of the Faculty of Medicine Jena
University Hospital
Jena, Germany
Berg Gunnar, Prof. Dr. Dr.
Vice-President Leopoldina
Halle, Germany
Betsch Cornelia, PD Dr.
Social, Organisational and Economic Psychology,
University of Erfurt
Erfurt, Germany
Böttiger Bernd, Prof. Dr.
Director of the Department of Anaesthesiology and Intensive
Care Medicine, University Hospital Cologne
Cologne, Germany
Brakhage Axel, Prof. Dr.
Director, Leibniz Institute for Natural Product Research
and Infection Biology, Hans Knöll Institute; Chairman,
InfectControl2020
Jena, Germany
Briegel Josef, Prof. Dr.
Speaker, SepNet Clinical Trials Group/ Klinik für Anästhesiologie,
LMU Munich
Munich, Germany
Brunkhorst Frank M., Prof. Dr.
Head, ZKS; Endowed Professorship for Clinical Sepsis Research,
Department for Anesthesiology and Intensive Care Medicine,
Jena University Hospital
Jena, Germany
Bucher Michael, Prof. Dr.
Director, Department of Anesthesiology and Operative Intensive
Care Medicine, University Hospital Halle (Saale)
Halle/Saale, Germany
13
Daniels Ron, Dr.
CEO UK Sepsis Trust; CEO Global Sepsis Alliance
Birmingham, UK
Ermantraut Eugen
CEO Blink GmbH; Past CEO, Alere Technologies GmbH
Jena, Germany
Finfer Simon, Prof. Dr.
Professorial Fellow, George Institute for Global Health, Senior
Staff Specialist in Intensive Care; Global Sepsis Alliance Board
Member; Royal North Shore Hospital of Sydney and Sydney
Adventist Hospital
Sydney, Australia
Gastmeier Petra, Prof. Dr.
Director, German National Reference Center for Surveillance of
Nosocomial Infections, Institute for Hygiene and Environmental
Medicine, Charité - University Medicine
Berlin, Germany
Gattinoni Luciano, Prof. Dr.
Chief of the Department of Anesthesia, Resuscitation and Pain
Therapy, Policlinico Hospital of Milan,
University of Milan, Italy
Gerlach Herwig, Prof. Dr.
Director, Clinic for Anesthesiology and Critical Care Medicine,
Vivantes - Klinikum Neukoelln; President, German Sepsis Society
Berlin, Germany
Hamilton Vida, M.D.
National Clinical Lead Sepsis, Health Service Executive (HSE)
Dublin, Ireland
Hecker Michael, Prof. Dr.
Professor emeritus, Member German Academy of Sciences
Leopoldina
Greifswald, Germany
Hein Tillmann, M.D.
Metropolitan Anesthesia Consultants, LLP
Dallas, Texas, USA
14
Heinz Dirk, Prof. Dr.
Scientific Director, Helmholtz Center for Infection Research; ViceChairman Executive Board, German Center for Infection Research
Braunschweig, Germany
Kissoon Niranjan, Prof. Dr.
Associate Head, Division of Critical Care, Department of
Pediatrics, University of British Columbia; Vice- President,
Medical Affairs, BC Children’s Hospital
Vancouver, Canada
Koch Thea, Prof. Dr.
Director, Clinic for Anesthesiology and Critical Care Medicine,
University Hospital Carl Gustav Carus Dresden; President German
Society of Anesthesiology and Intensive Medicine DGAI
Dresden, Germany
Kurzai Oliver, Prof. Dr.
Speaker, Center for Innovation Competence Septomics; Leibniz
Institute for Natural Product Research and Infection Biology,
Hans Knöll Institute
Jena, Germany
Mitchell M Levy, M.D.
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Alpert Medical School at Brown University
Director, Medical Intensive Care Unit
Rhode Island Hospital
Providence, RI USA
Liebenberg Volker, Dr.
BRAHMS/ ThermoFisher, Director Global Medical Affairs
Hennigsdorf, Germany
Löffler Bettina, Prof. Dr.
Director, Institute for Medical Microbiology, Jena University
Hospital
Jena, Germany
Löffler Markus, Prof. Dr.
Director, Institute for Medical Informatics, Statistics and
Epidemiology (IMISE), Leipzig University
Leipzig, Germany
Lugan Meinrad, Dr.
Board Director, B. Braun Melsungen AG
Melsungen, Germany
15
Marshall John, Prof. Dr.
Director of Research, Critical Care Medicine, St. Michael’s
Hospital; Chair, International Forum for Acute Care Trialists
(InFACT); Past-Chair, International Sepsis Forum (ISF)
Toronto, Canada
Meier-Hellmann Andreas, Prof. Dr.
Anesthesiology, Intensive Care Medicine and Pain Therapy, Helios
Clinical Center
Erfurt, Germany
Mettenleiter Thomas C., Prof. Dr.
Friedrich Loeffler Institute, Federal Research Institute for Animal
Health
Greifswald - Insel Riems, Germany
Müller-Jung Joachim, Dr.
Frankfurter Allgemeine Zeitung/ Head of Department Natur &
Wissenschaft
Herschbach, Germany
Pletz Mathias, Prof. Dr.
Head, Center for Infectious Diseases and Infection Control;
Deputy CEO Center for Sepsis Control and Care, Jena University
Hospital
Jena, Germany
Popp Jürgen, Prof. Dr.
Scientific Director, Leibniz Institute of Photonic Technology e.V.;
Professor for Physical Chemistry, Friedrich Schiller University Jena
Jena, Germany
Quintel Michael, Prof. Dr.
Director, Department of Anesthesiology, Göttingen University
Hospital, Germany
Reinhart Konrad, Prof. Dr.
Director, Department of Anesthesiology and Intensive Care, Jena
University Hospital; Chairman Global Sepsis Alliance; Chairman
Sepsis-Stiftung
Jena, Germany
Riedemann Niels C., Prof. Dr.
CEO InFlarX
Jena, Germany
Rietschel Ernst,Prof. Dr. Dr. h.c. mult.
Chairman of the Board of Directors, Berlin Institute of Health;
Former president of the Leibniz Association
Berlin, Germany
16
Rooney Kevin, Prof. Dr.
Professor of Care Improvement, University of the West of
Scotland, Paisley; National Clinical Advisor on Sepsis to
Healthcare Improvement Scotland
Paisley, UK
Rosenthal Walter, Prof. Dr.
President of the Friedrich Schiller University Jena
Jena, Germany
Rossaint Rolf, Prof. Dr.
Director, Department for Anesthesiology, University Hospital
Aachen
Aachen, Germany
Rüddel Hendrik, Dr.
Department of Anesthesiology and Intensive Care, Jena
University Hospital
Jena, Germany
Schulze P. Christian, MD, PhD
Director, Division of Cardiology, Angiology, Intensive Medical
Care and Pneumology
Jena University Hospital
Jena, Germany
Schüttler Jürgen, Prof. Dr. med. Dr. h.c.
Director, Department of Anesthesiology
Erlangen University Hospital, Germany
Shindo Nikki, Dr.
World Health Organization, Department of Pandemic and
Epidemic Diseases
Geneva, Switzerland
Spies Claudia, Prof. Dr.
Director, Department of Anesthesiology and Operative Intensive
Care Medicine, Charité, Berlin
Berlin, Germany
Steiner Achim
UNEP Executive Director and Under-Secretary-General of the
United Nations
Nairobi, Kenya
Stöbe Tankred, Dr.
Chairman; Board of Médecins Sans Frontières Germany
Berlin, Germany
17
Struck Joachim, Dr.
Chief Research Officer, AdrenoMed AG
Hennigsdorf, Germany
Suter Peter M, Prof. Dr.
President, Swiss Medical Board; Former President, Swiss Academy
of Medical Sciences, National Ethics Committee
Geneva, Switzerland
Suttorp Norbert, Prof. Dr.
Director, Clinic for Infectious Diseases and Pneumology,
Charité, Berlin
Berlin, Germany
Tiefensee Wolfgang
Thuringian Minister for Economic Affairs, Science and Digital
Society
Erfurt, Germany
Trumann Arne
Sepsis survivor
Heeslingen, Germany
Van Aken Hugo, Prof. Dr. Dr.
Director, Department of Anesthesiology, Intensive Care Medicine
and Pain Therapy
Muenster University Hospital, Germany
Weigand Markus, Prof. Dr.
Medical Director, Department for Anesthesiology, Heidelberg
University Hospital
Heidelberg, Germany
Welte Tobias, Prof. Dr.
Chairman, CapNetz Foundation; Head, Department of
Respiratory Medicine, Hannover Medical School
Hannover, Germany
Werdan Karl, Prof. Dr.
Professor Emeritus and former Director; Department for Internal
Medicine III, University Hospital Halle/Saale
Halle/Saale, Germany
Wieler Lothar-Heinz, Prof. Dr.
President, Robert Koch Institute
Berlin, Germany
18
Scientific organizers
Prof. Dr. Michael Bauer
Center for Sepsis Control and Care
Jena University Hospital
Prof. Dr. Axel Brakhage, ML
InfectControl2020
Leibniz Institute for Natural Product
Research and Infection Biology,
Hans Knöll Institute
Prof. Dr. Konrad Reinhart, ML (Coordinator)
Department of Anesthesiology and
Intensive Care Medicine
Jena University Hospital
Registration
www.cscc.uniklinikum-jena.de/leopoldina_symposium.html
19
Supporters
20
.................................................................................................
Fax
.................................................................................................
Datum, Unterschrift
.................................................................................................
Telefon
.................................................................................................
E-Mail
........................................................................................................................................................................................................
Postadresse
........................................................................................................................................................................................................
Funktion/Position
........................................................................................................................................................................................................
Einrichtung
........................................................................................................................................................................................................
Name, Vorname, Titel
Ich möchte mich zur Teilnahme am Leopoldina-Symposium am
11.03.2016 anmelden.
Ich möchte mich zur Teilnahme am Leopoldina-Symposium am
10.03.2016 anmelden.
Bitte senden Sie diesen Abschnitt per Fax (03641 9-323102).
Klinik für Anästhesiologie
und Intensivmedizin
Universitätsklinikum Jena
Erlanger Allee 101
07747 Jena
Daniela Küfner
Karte
bitte
freimachen

21
Sepsis
The challenges of science,
politics and society
Leopoldina Symposium
10 – 11 March 2016
Main Lecture Hall (Aula)
Friedrich Schiller University Jena
Fürstengraben 1 | 07743 Jena
Foto: © Name des Fotografen
22
23
Contact
Prof. Dr. Konrad Reinhart
Department of Anaesthesiology and Intensive Care Medicine
Jena University Hospital
Tel.: +49 (0)3641 9-323101
GEFÖRDERT VOM